Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Payables (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Payables data on record, last reported at $40.4 million in Q3 2025.

  • For Q3 2025, Payables rose 58.67% year-over-year to $40.4 million; the TTM value through Sep 2025 reached $40.4 million, up 58.67%, while the annual FY2024 figure was $31.2 million, 119.59% up from the prior year.
  • Payables reached $40.4 million in Q3 2025 per NWBO's latest filing, up from $40.0 million in the prior quarter.
  • Across five years, Payables topped out at $40.4 million in Q3 2025 and bottomed at $9.7 million in Q1 2021.
  • Average Payables over 5 years is $24.0 million, with a median of $22.4 million recorded in 2023.
  • Peak YoY movement for Payables: tumbled 45.62% in 2023, then skyrocketed 119.59% in 2024.
  • A 5-year view of Payables shows it stood at $14.1 million in 2021, then surged by 85.3% to $26.1 million in 2022, then crashed by 45.62% to $14.2 million in 2023, then surged by 119.59% to $31.2 million in 2024, then rose by 29.82% to $40.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $40.4 million in Q3 2025, $40.0 million in Q2 2025, and $40.4 million in Q1 2025.